Leadership

Mr. Ilan Hadar

CEO

Ilan brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Ilan has been instrumental in building companies from start-ups to hundreds of millions of dollars in operations. He successfully took part in the development, approval, and launch of new pharmaceutical products in the U.S. and Israel. Ilan has also been responsible for leading the operations, R&D, manufacturing, regulatory, and corporate finance for premier healthcare companies in the U.S. and Israel.

Currently, Ilan is serving as the CEO of Painreform Ltd. (“PRFX”) in addition to Silenseed, Painreform proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post-surgically. Prior to joining Painreform and Silenseed, Ilan served as Country Manager Israel and CFO at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since 2014, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., as well as a focus on capital markets and M&A. Prior to Foamix, Ilan was Finance Director at Pfizer Pharmaceutical Ltd., where he oversaw all commercial, financial and operational activities of the local entity. Prior to that, Ilan served as Finance Manager at HP Indigo Ltd, a world-leading company in digital printing. Prior to that, Ilan was Finance Director at BAE Systems (FTSE:BA), the third-largest defence company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2016, Ilan was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions, where he was successful in building the company from the incubator stage to a multinational, multi-million dollar revenue-generating company. Ilan serves on the Board of Directors at Kadimastem, a public Israeli biopharmaceutical company (TASE: KDST). Ilan received his MBA in Finance and Business Entrepreneurship and B.A. degree at The Hebrew University in Jerusalem, Israel.

Revital Maor-Aloni, PhD

Vice President Quality

Dr. Maor-Aloni is a Senior Manager, highly experienced in the biotech, pharma and medical device industries combined with extensive experience in leading quality processes for compliance with FDA regulations, ICH, CFR, Medical Device Directive 93/42/EEC, ISO (including ISO 17025, ISO 13485), Eudralex, cGMP, GLP and IMOH guidelines. She is experienced in leading company quality strategies based on risk management as well as leading process and product control strategies.
She is supervised all quality aspects QA, QC and validation as well as orchestrated CMC activities and overseen risk management and assessments, policies, procedures and guidance documents, failure investigations,
quality events and CAPA, training and qualification, supplier quality and more.
Revital holds a PhD in Microbiology and Immunology from Ben-Gurion University, and a Post-Doctorate in Molecular Biology from Weizmann Institute of Science.

Mitchell Shirvan, Ph.D

Mitchell Shirvan, Ph.D

CSO

Prior to joining Silenseed Dr. Shirvan has served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since August 2017.

Dr. Shirvan has been with Foamix since March 2014.  He has over 25 years of industry experience, previously holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012.

From 1992 until 2008, Dr. Shirvan held various positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior Manager, Research & Development.

Prior to this he was a research fellow at the US National Institutes of Health.  Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem, and an MBA from the University of Bradford.

Racheli Gabai Malka, Ph. D

VP Pharmaceutical Development

Dr Gabai Malka Joined Silenseed in February 2009 and leads the development of the formulation and the production of the KRAS-LODER from the concept stage and up to Phase II.

Dr Gabai Malka holds a B.Sc. in Chemistry and a M.Sc. in Chemistry both from the Hebrew University in Jerusalem and holds a Ph.D. and a Post-Doctorate in Chemistry from the Weizmann institute of science in Rehovot, Israel.

Dr Gabai Malak is a co-author of 12 scientific papers and co-inventor of 8 of the Silenseed’s granted patents.

Orit Pollack–Shragai, M.Sc, MBA

VP Clinical Affairs

Mrs. Pollack Shragai brings  over  two  decades  of relevant academic education, research and work experience in the biomed industry working for CRO, big pharma and start-up companies, managing local and international clinical trials (including mega trials) in drugs and medical devices.

Prior to joining Silenseed, Mrs. Pollack Shragai served as Director of Clinical Operations and Active Advisor to several pharmaceutical companies.

Mrs. Pollack Shragai holds  a  B.Sc  in  Food  Engineering  and  Biotechnology  from  the  Technion  in  Israel,  M.Sc  in Biotechnology  from  the  Hebrew  University  and  MBA  from  the  College  of  Management Academic Studies

Michal Yaron

Mrs. Yaron holds 17 years of professional regulatory and product development experience across the pharmaceutical industry, with products from early stage through POC and regulatory approvals by multiple health authorities. Previously Mrs. Yaron held Regulatory Affairs managerial positions at Sol-Gel Technologies, Polypid, and Teva Pharmaceuticals Ltd. Mrs. Yaron Holds a B.Sc. degree in Chemistry Engineering.